Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Articolo
Data di Pubblicazione:
2023
Citazione:
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial / Tempero, M.A., Pelzer, U., O'Reilly, E.M., Winter, J., Oh, D., Li, C., Tortora, G., Chang, H., Lopez, C.D., Bekaii-Saab, T., Ko, A.H., Santoro, A., Park, J.O., Noel, M.S., Frassineti, G.L., Shan, Y., Dean, A., Riess, H., Van Cutsem, E., Berlin, J., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 41:11(2023), pp. 2007-2019. [10.1200/JCO.22.01134]
Abstract:
This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Tempero, Margaret A; Pelzer, Uwe; O'Reilly, Eileen M; Winter, Jordan; Oh, Do-Youn; Li, Chung-Pin; Tortora, Giampaolo; Chang, Heung-Moon; Lopez, Charles D; Bekaii-Saab, Tanios; Ko, Andrew H; Santoro, Armando; Park, Joon Oh; Noel, Marcus S; Frassineti, Giovanni Luca; Shan, Yan-Shen; Dean, Andrew; Riess, Hanno; Van Cutsem, Eric; Berlin, Jordan; Philip, Philip; Moore, Malcolm; Goldstein, David; Tabernero, Josep; Li, Mingyu; Ferrara, Stefano; Le Bruchec, Yvan; Zhang, George; Lu, Brian; Biankin, Andrew V; Reni, Michele
Link alla scheda completa:
Link al Full Text:
Pubblicato in: